BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38351809)

  • 1. A concise review of flow cytometric methods for minimal residual disease assessment in childhood B-cell precursor acute lymphoblastic leukemia.
    Baldzhieva A; Burnusuzov HA; Murdjeva MA; Dimcheva TD; Taskov HB
    Folia Med (Plovdiv); 2023 Jun; 65(3):355-361. PubMed ID: 38351809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry].
    Zhang LP; Cheng YF; Liu GL; Lu AD; Liu YR; Wang H
    Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):481-5. PubMed ID: 16083543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
    Gaipa G; Basso G; Biondi A; Campana D
    Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
    Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
    Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.
    Schumich A; Maurer-Granofszky M; Attarbaschi A; Pötschger U; Buldini B; Gaipa G; Karawajew L; Printz D; Ratei R; Conter V; Schrappe M; Mann G; Basso G; Dworzak MN;
    Pediatr Blood Cancer; 2019 May; 66(5):e27590. PubMed ID: 30561169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
    Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
    Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Automated Flow Cytometric MRD Assessment in Childhood Acute B- Lymphoblastic Leukemia Using Supervised Machine Learning.
    Reiter M; Diem M; Schumich A; Maurer-Granofszky M; Karawajew L; Rossi JG; Ratei R; Groeneveld-Krentz S; Sajaroff EO; Suhendra S; Kampel M; Dworzak MN;
    Cytometry A; 2019 Sep; 95(9):966-975. PubMed ID: 31282025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.
    Karawajew L; Dworzak M; Ratei R; Rhein P; Gaipa G; Buldini B; Basso G; Hrusak O; Ludwig WD; Henze G; Seeger K; von Stackelberg A; Mejstrikova E; Eckert C
    Haematologica; 2015 Jul; 100(7):935-44. PubMed ID: 26001791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of minimal residual disease in acute leukemia by multiparametric flow cytometry.
    Kusenda J; Fajtova M; Kovarikova A
    Neoplasma; 2014; 61(2):119-27. PubMed ID: 24299307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How I Diagnose Minimal/Measurable Residual Disease in B Lymphoblastic Leukemia/Lymphoma by Flow Cytometry.
    Cherian S; Soma LA
    Am J Clin Pathol; 2021 Jan; 155(1):38-54. PubMed ID: 33236071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation of a simplified flow cytometric assays for minimal residual disease monitoring in childhood acute lymphoblastic leukemia.
    Vinhas E; Lucena-Silva N; Pedrosa F
    Cytometry B Clin Cytom; 2018 Jan; 94(1):94-99. PubMed ID: 27342632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Minimal Residual Disease Detection by Next Generation Flow Cytometry on Outcome of Egyptian Patients with Acute Lymphoblastic Leukemia.
    Algamal RA; Abu Samra NK; Ellashery RA; Abd-EL-Hameed SAE; Shahin DA
    Asian Pac J Cancer Prev; 2023 Oct; 24(10):3577-3584. PubMed ID: 37898866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities.
    Chen X; Wood BL
    Blood Rev; 2017 Mar; 31(2):63-75. PubMed ID: 27742133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia.
    Neale GA; Coustan-Smith E; Pan Q; Chen X; Gruhn B; Stow P; Behm FG; Pui CH; Campana D
    Leukemia; 1999 Aug; 13(8):1221-6. PubMed ID: 10450750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. United we stand, divided we fall. Multicentre standardization of measurable residual disease assessment in acute leukaemia is the way forward.
    Chatterjee G; Patkar N
    Br J Haematol; 2023 Feb; 200(3):277-279. PubMed ID: 36282207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High frequency of heat shock protein 27 overexpression is a highly effective, high-coverage marker for minimal residual disease detection in children with B-cell acute lymphoblastic leukemia.
    Chou SW; Su YH; Lu MY; Chang HH; Yang YL; Lin DT; Lin KH; Coustan-Smith E; Jou ST
    Pediatr Blood Cancer; 2023 Jan; 70(1):e29990. PubMed ID: 36250996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical significance of dynamic monitoring the minimal residual disease in childhood B-lineage acute lymphoblastic leukemia by multiparameter flow cytometry].
    Guo DD; Zhao WL; Zhang YL; Pang L; Che L; He HL; Chai YH; Ji ZH; Ji XQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1346-51. PubMed ID: 23257430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical significance for minimal residual disease detection by 4 color flow cytometry in adult and childhood B lineage acute lymphoblastic leukemia].
    Liu YR; Zhang LP; Chang Y; Cheng YF; Fu JY; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):302-5. PubMed ID: 16875577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute lymphoblastic leukemia: diagnosis and detection of minimal residual disease following therapy.
    Digiuseppe JA
    Clin Lab Med; 2007 Sep; 27(3):533-49, vi. PubMed ID: 17658406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing.
    Coustan-Smith E; Campana D
    Best Pract Res Clin Haematol; 2010 Sep; 23(3):347-58. PubMed ID: 21112034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.